VanEck Uranium & Nuclear ETF vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck Uranium & Nuclear ETF trades at $103.35 (market cap $3.51B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.9× VanEck Uranium & Nuclear ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 8 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NLR | XBI | |
|---|---|---|
Market Cap | $3.51B | $10.11B |
Volume | 414,516 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $164.37 | $169.55 |
52-Week Low | $102.38 | $104.99 |
Typical Hold Time | 8 Days | 38 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →